Table 1 Baseline demographics

From: Routine blood investigations have limited utility in surveillance of aggressive lymphoma in asymptomatic patients in complete remission

Ā 

All patients nā€‰=ā€‰346 (%)

Median age (range)

54 (17ā€“91)

Gender

Ā ā€ƒMale

202 (58)

Ā ā€ƒFemale

144 (42)

Stage

Ā ā€ƒIā€“II

168 (49)

Ā ā€ƒIIā€“IV

178 (51)

Subtype

Ā ā€ƒDLBCL

187 (54)

Ā ā€ƒHL

119 (34)

Ā ā€ƒBL

22 (6)

Ā ā€ƒTCL

18 (5)

B symptoms

201(58)

>1 extranodal site

68 (20)

Bone marrow involvement

39 (11)

Performance status

Ā ā€ƒ0ā€“1

306 (88)

Ā ā€ƒā‰„2

40 (12)

Prognostic score

ā€ƒLow riska

280 (81)

ā€ƒHigh riskb

66 (19)

Treatment

Ā ā€ƒChemotherapy alone

238 (69)

Ā ā€ƒChemotherapy and radiotherapy

108 (31)

  1. aLow riskā€‰=ā€‰International Prognostic Index for DLBCL and TCL: 0ā€“2; Hasenclever score for HL: 0ā€“3; prognostic score for Burkittā€™s lymphoma: 0ā€“2.
  2. bHigh riskā€‰=ā€‰International Prognostic Index for DLBCL and TCL: >3; Hasenclever score for HL: >4; prognostic score for Burkittā€™s lymphoma: >3
Back to article page